- Home
- PHUN vs AVTX Comparison
PHUN vs AVTX Comparison
Compare PHUN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- AVTX
- Stock Information
- Founded
- PHUN 2009
- AVTX 2011
- Country
- PHUN United States
- AVTX United States
- Employees
- PHUN N/A
- AVTX N/A
- Industry
- PHUN EDP Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- AVTX Health Care
- Exchange
- PHUN Nasdaq
- AVTX Nasdaq
- Market Cap
- PHUN 64.1M
- AVTX 57.4M
- IPO Year
- PHUN N/A
- AVTX 2015
- Fundamental
- Price
- PHUN $3.42
- AVTX $4.94
- Analyst Decision
- PHUN Buy
- AVTX Strong Buy
- Analyst Count
- PHUN 2
- AVTX 7
- Target Price
- PHUN $7.75
- AVTX $31.00
- AVG Volume (30 Days)
- PHUN 338.2K
- AVTX 99.4K
- Earning Date
- PHUN 08-07-2025
- AVTX 08-11-2025
- Dividend Yield
- PHUN N/A
- AVTX N/A
- EPS Growth
- PHUN N/A
- AVTX N/A
- EPS
- PHUN N/A
- AVTX N/A
- Revenue
- PHUN $2,956,000.00
- AVTX $441,000.00
- Revenue This Year
- PHUN $3.01
- AVTX N/A
- Revenue Next Year
- PHUN $50.72
- AVTX N/A
- P/E Ratio
- PHUN N/A
- AVTX N/A
- Revenue Growth
- PHUN N/A
- AVTX N/A
- 52 Week Low
- PHUN $2.22
- AVTX $3.39
- 52 Week High
- PHUN $14.60
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- PHUN 59.76
- AVTX 57.06
- Support Level
- PHUN $2.95
- AVTX $4.50
- Resistance Level
- PHUN $3.10
- AVTX $5.05
- Average True Range (ATR)
- PHUN 0.17
- AVTX 0.32
- MACD
- PHUN 0.02
- AVTX 0.03
- Stochastic Oscillator
- PHUN 84.58
- AVTX 81.36
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).